首页 | 本学科首页   官方微博 | 高级检索  
检索        


Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
Authors:Robert A Hodgson  Paul J Bedard  Geoffrey B Varty  Tatiana M Kazdoba  Therese Di Paolo  Michael E Grzelak  Annamarie J Pond  Abdallah HadjTahar  Nancy Belanger  Laurent Gregoire  Aurelie Dare  Bernard R Neustadt  Andrew W Stamford  John C Hunter
Institution:aDepartment of Neurobiology, Merck and Co. Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA;bNeuroscience Research Unit, Laval University Medical Center, CHUL Pavilion and Faculty of Medicine, Laval University, Quebec, Canada;cMolecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), Quebec, Canada;dDepartment of Chemical Research, Merck and Co. Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA;eDepartment of Neurobiology, Merck and Co. Inc. 770 Sumneytown Pike, West Point, PA 19486, USA
Abstract:Parkinson's Disease (PD) and Extrapyramidal Syndrome (EPS) are movement disorders that result from degeneration of the dopaminergic input to the striatum and chronic inhibition of striatal dopamine D2 receptors by antipsychotics, respectively. Adenosine A2A receptors are selectively localized in the basal ganglia, primarily in the striatopallidal (“indirect”) pathway, where they appear to operate in concert with D2 receptors and have been suggested to drive striatopallidal output balance. In cases of dopaminergic hypofunction, A2A receptor activation contributes to the overdrive of the indirect pathway. A2A receptor antagonists, therefore, have the potential to restore this inhibitor imbalance. Consequently, A2A receptor antagonists have therapeutic potential in diseases of dopaminergic hypofunction such as PD and EPS. Targeting the A2A receptor may also be a way to avoid the issues associated with direct dopamine agonists. Recently, preladenant was identified as a potent and highly selective A2A receptor antagonist, and has produced a significant improvement in motor function in rodent models of PD. Here we investigate the effects of preladenant in two primate movement disorder models. In MPTP-treated cynomolgus monkeys, preladenant (1 or 3 mg/kg; PO) improved motor ability and did not evoke any dopaminergic-mediated dyskinetic or motor complications. In Cebus apella monkeys with a history of chronic haloperidol treatment, preladenant (0.3–3.0 mg/kg; PO) delayed the onset of EPS symptoms evoked by an acute haloperidol challenge. Collectively, these data support the use of preladenant for the treatment of PD and antipsychotic-induced movement disorders.
Keywords:Preladenant  MPTP  Extrapyramidal Syndrome  Monkey  Parkinson's Disease  A2A  Adenosine  Movement disorder
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号